Claims
- 1. A composition comprising an amount of a phosphodiesterase type 4 (PDE4) inhibitor effective to inhibit phosphodiesterase type 4 activity in a neuron when administered subcutaneously to a mammal for a prolonged period of time.
- 2. A composition comprising an amount of a PDE4 inhibitor effective to increase cAMP levels in a neuron when administered subcutaneously to a mammal for a prolonged period of time.
- 3. A composition comprising an amount of a PDE4 inhibitor which, when administered subcutaneously to a mammal for a prolonged period of time, promotes neuronal growth in the presence of MAG or myelin.
- 4. A composition according to any one of claims 1-3, wherein the PDE4 inhibitor is rolipram.
- 5. A composition according to any one of claims 1-3, wherein the PDE4 inhibitor is administered at a dose of 0.1 to 10 umol/kg/hour, wherein said dose is administered for at least 24 hours.
- 6. The composition according to claim 5, wherein the PDE4 inhibitor is administered at a dose of 0.1 to 3 umol/kg/hour.
- 7. The composition according to claim 5, wherein the PDE4 inhibitor is administered for at least a period of time selected from the group consisting of 48 hours, 72 hours, 96 hours, one week, two weeks, one month, two months, three months, six months and twelve months.
- 8. A method for regulating neural growth or regeneration in the nervous system of a mammal, comprising the step of administering to said mammal for a prolonged period of time a composition comprising a therapeutically effective amount of an agent that inhibits PDE4 activity in a neuron of the mammal.
- 9. A method for the treatment of an injury or damage to nervous tissue or neurons in a patient in need thereof, comprising the step of administering to said patient for a prolonged period of time a composition comprising a therapeutically effective amount of an agent that inhibits PDE4 activity in a neuron.
- 10. A method for treating neural degeneration associated with disorders or diseases in a patient in need thereof, comprising the step of administering to the patient for a prolonged period of time a composition comprising a therapeutically effective amount of an agent which inhibits PDE4 activity in a neuron.
- 11. A method for treating a disease, disorder or condition associated with apoptosis in a patient in need thereof comprising the step of administering to the patient for a prolonged period of time a composition comprising a therapeutically effective amount of an agent which inhibits PDE4 activity in a neuron.
- 12. A method for treating a neurodegenerative disease selected from the group consisting of amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and Huntington's disease, in a patient in need thereof, said method comprising the step of administering for a prolonged period of time to said patient a composition comprising a therapeutically effective amount of an agent which inhibits PDE4 activity in a neuron.
- 13. The method of any one of claims 9-12, wherein the PDE4 inhibitor is administered continuously or repeatedly for at least 24 hours.
- 14. The method of claim 13, wherein the PDE4 inhibitor is administered continuously or repeatedly for at least a period of time selected from the group consisting of 48 hours, 72 hours, 96 hours, one week, two weeks, one month, two months, three months, six months and twelve months.
- 15. The method of any one of claims 8-14, wherein the PDE4 inhibitor is administered subcutaneously.
- 16. The method of any one of claims 8-15, wherein the PDE4 inhibitor is rolipram.
- 17. The method of any one of claims 8-16, wherein the patient is a human subject.
- 18. The method according to any one of claims 8-17, wherein the PDE4 inhibitor is administered at a dose of 0.1 to 10 umol/kg/hour.
- 19. The method according to claim 18, wherein the PDE4 inhibitor is administered at a dose of 0.1 to 3 umol/kg/hour.
Parent Case Info
[0001] This application claims benefit of U.S. Provisional Application No. 60/245,319, filed Nov. 2, 2000, which is herein incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60245319 |
Nov 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US01/46846 |
Nov 2001 |
US |
Child |
10414506 |
Apr 2003 |
US |